Literature DB >> 3142565

Vasoactive and atherogenic effects of cigarette smoking: a study of monozygotic twins discordant for smoking.

R Lassila1, H W Seyberth, A Haapanen, H Schweer, M Koskenvuo, K E Laustiola.   

Abstract

The mechanism by which atherosclerotic disease is induced by cigarette smoking has not yet been identified unequivocally. Chronic cigarette smoking and the generation of vasoactive prostanoids and the size of carotid atherosclerotic plaques were studied in nine pairs of identical male twins discordant for smoking for over 20 years. The urinary excretion of 2,3-dinor-thromboxane B2 (thromboxane B2 metabolite) of the smoking twin was significantly higher (on average 1.8 times higher) in every pair and that of 2,3-dinor-6-keto-prostaglandin F1 alpha (prostacyclin metabolite) was significantly higher (on average 1.3 times higher) in eight of the nine pairs. The ratio of excretion of these metabolites was significantly higher, being 4.0 (95% confidence interval 2.7 to 5.4) among the smokers compared with 2.9 (2.1 to 3.8) among the non-smokers, thus favouring a mechanism of vasoconstriction. Excretion of the thromboxane B2 metabolite was related to the urinary concentrations of nicotine metabolites. Atherosclerotic plaques detected by ultrasonography in the carotid arteries were significantly larger among smokers but did not correlate with the urinary excretion of prostacyclin and thromboxane B2 metabolites or intensity of smoking. Smoking was concluded to induce activation of platelets by an effect mediated by nicotine. The increased prostacyclin production, on the other hand, suggested a compensatory mechanism for the general vasoconstrictive properties of cigarette smoking.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142565      PMCID: PMC1834683          DOI: 10.1136/bmj.297.6654.955

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  31 in total

1.  Individual cigarette usage: self-reported data as a function of respondent-reported data.

Authors:  C A McMahan; M L Richards; J P Strong
Journal:  Atherosclerosis       Date:  1976 May-Jun       Impact factor: 5.162

2.  The Finnish Twin Registry: formation and compilation, questionnaire study, zygosity determination procedures, and research program.

Authors:  J Kaprio; S Sarna; M Koskenvuo; I Rantasalo
Journal:  Prog Clin Biol Res       Date:  1978

3.  Intermittent claudication: factors determining outcome.

Authors:  W G Hughson; J I Mann; D J Tibbs; H F Woods; I Walton
Journal:  Br Med J       Date:  1978-05-27

4.  Quantitative analysis of two dinor urinary metabolites of prostaglandin I2.

Authors:  P Falardeau; J A Oates; A R Brash
Journal:  Anal Biochem       Date:  1981-08       Impact factor: 3.365

5.  Relationships of the platelet aggregate ratio to serum cholesterol concentration, smoking and age.

Authors:  J W Davis; P E Phillips; H D Lewis; R F Davis
Journal:  Postgrad Med J       Date:  1981-03       Impact factor: 2.401

6.  Cigarette smoking and atherosclerosis in autopsied men.

Authors:  J P Strong; M L Richards
Journal:  Atherosclerosis       Date:  1976 May-Jun       Impact factor: 5.162

7.  Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events.

Authors:  P E Cryer; M W Haymond; J V Santiago; S D Shah
Journal:  N Engl J Med       Date:  1976-09-09       Impact factor: 91.245

8.  Mapping of the late promoter of simian virus 40.

Authors:  S W Hartzell; B J Byrne; K N Subramanian
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Inhibition by nicotine of the formation of prostacyclin-like activity in rabbit and human vascular tissue.

Authors:  T Sonnenfeld; A Wennmalm
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

10.  Hypersensitivity to tobacco antigen.

Authors:  C G Becker; T Dubin; H P Wiedemann
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

View more
  10 in total

Review 1.  Non-steroidal anti-inflammatory drugs and peptic ulcers.

Authors:  C J Hawkey
Journal:  BMJ       Date:  1990-02-03

Review 2.  Vessel wall-related risk factors in acute vascular events.

Authors:  L Badimon; J J Badimon; M Cohen; J H Chesebro; V Fuster
Journal:  Drugs       Date:  1991       Impact factor: 9.546

3.  Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: similarities and differences.

Authors:  Ernest Palomeras Soler; Virgina Casado Ruiz
Journal:  Curr Cardiol Rev       Date:  2010-08

4.  Smoking and choroidal thickness in patients over 65 with early-atrophic age-related macular degeneration and normals.

Authors:  E J Sigler; J C Randolph; J I Calzada; S Charles
Journal:  Eye (Lond)       Date:  2014-05-16       Impact factor: 3.775

5.  Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers.

Authors:  G Bolinder; L Alfredsson; A Englund; U de Faire
Journal:  Am J Public Health       Date:  1994-03       Impact factor: 9.308

6.  Biometrical genetic analysis of the cotwin control design.

Authors:  D L Duffy
Journal:  Behav Genet       Date:  1994-07       Impact factor: 2.805

7.  Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia.

Authors:  J A Wedzicha; D Syndercombe-Court; K C Tan
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

8.  The effects of smoking and hypertensive disorders on fetal growth.

Authors:  Svein Rasmussen; Lorentz M Irgens
Journal:  BMC Pregnancy Childbirth       Date:  2006-04-21       Impact factor: 3.007

9.  Smoking as a crucial independent determinant of stroke.

Authors:  Seana L Paul; Amanda G Thrift; Geoffrey A Donnan
Journal:  Tob Induc Dis       Date:  2004-06-15       Impact factor: 2.600

10.  Is grand-parental smoking associated with adolescent obesity? A three-generational study.

Authors:  M M Dougan; A E Field; J W Rich-Edwards; S E Hankinson; R J Glynn; W C Willett; K B Michels
Journal:  Int J Obes (Lond)       Date:  2015-09-21       Impact factor: 5.095

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.